Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H11NO2 |
| Molecular Weight | 117.1463 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CC([O-])=O
InChI
InChIKey=KWIUHFFTVRNATP-UHFFFAOYSA-N
InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
| Molecular Formula | C5H11NO2 |
| Molecular Weight | 117.1463 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Betaine is a methyl derivative of glycine first isolated from the juice of sugar beets. Betaine is found in many common foods, but concentrated significantly in beets, spinach, wheat foods, and shellfish. In addition, betaine can be synthesized within the human body. Betaine participates in the methionine cycle, which produces vital biomolecules including proteins, hormones, phospholipids, polyamines, and nutrients. Betaine is used as a dietary supplement and has a beneficial effect on the human health. In the USA, FDA approved a betaine-containing drug Cystadane for the treatment of homocystinuria. The drug acts as a methyl group donor in the remethylation of homocysteine to methionine.
CNS Activity
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CYSTADANE Approved UseCystadane is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect. Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.939 mM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.456 mM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.518 mM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.528 mM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.38 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
41.17 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The organic osmolyte betaine induces keratin 2 expression in rat epidermal keratinocytes - A genome-wide study in UVB irradiated organotypic 3D cultures. | 2015-12-25 |
|
| Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats. | 2015-05 |
|
| 5-Methyl phenazine-1-carboxylic acid: a novel bioactive metabolite by a rhizosphere soil bacterium that exhibits potent antimicrobial and anticancer activities. | 2015-04-25 |
|
| Betanin reduces the accumulation and cross-links of collagen in high-fructose-fed rat heart through inhibiting non-enzymatic glycation. | 2015-02-05 |
|
| Proteomics analysis of altered cellular metabolism induced by insufficient copper level. | 2014-11-10 |
|
| Betaine supplementation protects against renal injury induced by cadmium intoxication in rats: role of oxidative stress and caspase-3. | 2014-03 |
|
| Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency. | 2014-02 |
|
| Alterations in hepatic metabolism of sulfur amino acids in non-obese type-2 diabetic Goto-Kakizaki rats. | 2013-07-05 |
|
| A urinary metabonomics study on biochemical changes in yeast-induced pyrexia rats: a new approach to elucidating the biochemical basis of the febrile response. | 2013-06-25 |
|
| Wilson's disease: changes in methionine metabolism and inflammation affect global DNA methylation in early liver disease. | 2013-02 |
|
| Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. | 2013-01 |
|
| Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. | 2012 |
|
| S-Adenosylhomocysteine enhances DNA damage through increased β-amyloid formation and inhibition of the DNA-repair enzyme OGG1b in microglial BV-2 cells. | 2011-12-18 |
|
| Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2. | 2011-11-04 |
|
| Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors. | 2010-05 |
|
| Antioxidant defense of betaine against isoprenaline-induced myocardial infarction in rats. | 2010-03 |
|
| Identification of a novel organic anion transporter mediating carnitine transport in mouse liver and kidney. | 2010 |
|
| Protective effect of betaine on changes in the levels of lysosomal enzyme activities in heart tissue in isoprenaline-induced myocardial infarction in Wistar rats. | 2009-11 |
|
| Assessment of the effect of betaine on p16 and c-myc DNA methylation and mRNA expression in a chemical induced rat liver cancer model. | 2009-07-30 |
|
| S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. | 2009-07 |
|
| Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats. | 2009-02-12 |
|
| Characteristics of transport of selenoamino acids by epithelial amino acid transporters. | 2009-02-12 |
|
| Long follow up of betaine therapy in two Japanese siblings with cystathionine beta-synthase deficiency. | 2008-10 |
|
| Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase. | 2008-04-04 |
|
| Consideration of betaine and one-carbon sources of N5-methyltetrahydrofolate for use in homocystinuria and neural tube defects. | 2007-04 |
|
| Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. | 2006-11 |
|
| Maternal methyl supplements increase offspring DNA methylation at Axin Fused. | 2006-09 |
|
| Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. | 2005-10 |
|
| Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. | 2005-08-15 |
|
| Carbon tetrachloride-induced nephrotoxicity and protective effect of betaine in Sprague-Dawley rats. | 2003-08 |
|
| Betaine. Monograph. | 2003-05 |
|
| Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. | 2003-03 |
|
| Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. | 2003-02 |
|
| Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. | 2002-11 |
|
| Betaine and homocysteine concentrations in infant formulae and breast milk. | 2001-12 |
|
| Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. | 2001-09 |
|
| An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. | 2001-08-28 |
|
| Effects of amplification facilitators on diagnostic PCR in the presence of blood, feces, and meat. | 2000-12 |
|
| Simple method for the routine determination of betaine and N,N-dimethylglycine in blood and urine. | 1998-09 |
|
| Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. | 1997-11 |
|
| Strychnine-dependent allodynia in the urethane-anesthetized rat is segmentally distributed and prevented by intrathecal glycine and betaine. | 1995-12 |
|
| The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. | 1994-08 |
|
| Isolation of glycine betaine and proline betaine from human urine. Assessment of their role as osmoprotective agents for bacteria and the kidney. | 1987-03 |
Patents
Sample Use Guides
The usual dosage in adult and pediatric patients is 6 grams per day administered orally in divided doses of 3 grams twice daily. In pediatric patients less than 3 years of age, dosage may be started at 100 mg/kg/day divided in twice daily doses, and then increased weekly by 50 mg/kg increments.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921120
HeLa cells were treated with 0.1, 1.0, 5.0, 20.0, 100.0 mg/ml of betaine to evaluate the anticancer efficacy of the compound. The percentage of S phase cells in the low dose groups (< 5mg/ml) were distinctly higher than in high dose groups, and the rates of Sub-G1 phase were the opposite. A high concentration of betaine (>5.0mg/ml) significantly promoted the apoptosis of HeLa cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:50 GMT 2025
by
admin
on
Mon Mar 31 17:48:50 GMT 2025
|
| Record UNII |
3SCV180C9W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EPA PESTICIDE CODE |
103669
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
81794
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
NDF-RT |
N0000175805
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
NDF-RT |
N0000175804
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
XIAPEX (AUTHORIZED DUPUYTREN CONTRACTURE)
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CYSTADANE (AUTHORIZED HOMOCYSTINURIA)
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
DSLD |
2312 (Number of products:649)
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
WHO-ATC |
A16AA06
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
WHO-ATC |
A09AB02
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/01/045
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
WHO-VATC |
QA16AA06
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
DSLD |
625 (Number of products:495)
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
203-490-6
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
247
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
1065695
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
D001622
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
C81038
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
347
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
350374
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
107-43-7
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
3SCV180C9W
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
17750
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
7467
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
3SCV180C9W
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
1512
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
ALTERNATIVE | |||
|
SUB13055MIG
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
SUB23574
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
166511
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
m2451
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000089335
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
TRIMETHYLGLYCINE
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
DTXSID8022666
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
DB06756
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SOLVATE->ANHYDROUS | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |